Company Overview and News

 
Falco Announces $10 Million Secured Loan With Osisko Gold Royalties and Provides Corporate Update

2018-09-11 globenewswire
MONTREAL, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSXV: FPC) ("Falco" or the "Company") is pleased to announce the execution of a secured senior loan agreement with Osisko Gold Royalties Ltd (TSX: OR) ("Osisko") pursuant to which Osisko has agreed to loan $10 million to Falco and is also pleased to provide a corporate update.
FPC OKSWF OR OR OSKGF FPRGF

 
Osisko Enters Into $10 Million Secured Senior Loan Agreement With Falco Resources

2018-09-11 globenewswire
MONTRÉAL, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (TSX & NYSE: OR) is pleased to announce that it has entered into an agreement to provide Falco Resources Ltd. (“Falco”) (TSXV: FPC) with a secured senior C$10 million loan to Falco.
FPC OKSWF OR OR OSKGF BGMZF FPRGF

 
Falco Provides Exploration Program Update

2018-09-04 globenewswire
MONTRÉAL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (FPC: TSX-V) (“Falco” or the “Company”) is pleased to announce an update on the drilling program initiated in February 2018. The program consists in 25,000 metres of core drilling conducted mostly on three main properties.
FPC OKSWF OR OSKGF FPRGF

 
Osisko Metals Announces Changes to Management

2018-08-20 globenewswire
MONTREAL, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V: OM; FRANKFURT: OB5) is pleased to announce changes to its management team. Effective immediately, Mr. Robert Wares, currently Chairman of the Board of Osisko Metals, will be named Executive Chairman of the Company. Mr. Wares is a professional geologist with over 35 years’ experience in mineral exploration and development, and was one of the three original founders of Osisko Exploration/Osisko Mining Corp.
DNGDF FPC DNG AXXDF ADV DDEJF FPRGF TNMCF KMT

 
Globex Has a Very Busy Year So Far

2018-08-20 globenewswire
ROUYN-NORANDA, Quebec, Aug. 20, 2018 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz Stock Exchanges and GLBXF – OTCQX International) is pleased to inform shareholders that it has completed line cutting and magnetometer and VLF surveys over the area which covers the newly delineated South Shear on the Francoeur/Arntfield gold mines property where stripping, channel sampling and diamond drilling returned significant gold values (channel sampling up to 9.
BPUZF SYA DMNXF CGMLF EFRGF GAYMF TRSFF GWM CHN GLBXF FPC ERC NYR TRS FPRGF

 
Osisko Gold Royalties Ltd (OR) CEO Sean Roosen on Q2 2018 Results - Earnings Call Transcript

2018-08-05 seekingalpha
Osisko Gold Royalties Ltd (NYSE:OR) Q2 2018 Earnings Conference Call August 3, 2018 10:00 AM ET
FPC OKSWF OR OSKGF FPRGF VITFF VIT

1
Osisko Reports Second Quarter 2018 Results

2018-08-02 globenewswire - 1
MONTRÉAL, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) today announced its consolidated financial results for the second quarter ended June 30, 2018 and an update on matters following quarter-end.
FPC OKSWF OR OR OSKGF BGMZF FPRGF VITFF VIT

 
Osisko Declares 16th Consecutive Quarterly Dividend

2018-08-02 globenewswire
MONTREAL, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd ("Osisko" or the "Company") (TSX:OR) (NYSE:OR) is pleased to announce a third quarter 2018 dividend of $0.05 per common share. The dividend will be paid on October 15, 2018 to shareholders of record as of the close of business on September 28, 2018.
FPC OKSWF OR OR OSKGF BGMZF FPRGF VITFF VIT

9
Gold Mining Bull: Top News For June 2018

2018-07-03 seekingalpha - 1
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for May, in case you missed it.
AGCBF RIO RIO YRI KGI.DB CG CAGDF RTPPF FPC AUY OR RTNTF FPRGF SEMFF KL WPM SAND SSL SDDXF KGI OKSWF KGI.DB.A SNXZF RGLD AGC RIO OSKGF RGL

 
Early Warning News Release

2018-07-03 globenewswire
MONTREAL, July 03, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”) announces that it has completed the previously announced purchase from Falco Resources Ltd. (TSXV:FPC) (“Falco”) of a secured debenture having a principal amount of C$7,000,000 (the “Debenture”). The Debenture will, upon approval of the disinterested shareholders of Falco, become convertible (the “Conversion”) into units of Falco, with each unit comprised of one common share of Falco and one-half of one common share purchase warrant of Falco.
FPC OKSWF OR OR OSKGF BGMZF FPRGF

 
Falco Closes $7 Million Financing with Osisko

2018-07-03 globenewswire
MONTREAL, July 03, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSX-V:FPC) (“Falco” or the “Company”) is pleased to announce that it has closed its previously announced $7 million financing transaction (the “Debenture Financing”) with Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”). Under the terms of the Debenture Financing, Osisko purchased a secured debenture (the “Debenture”) having a principal amount of $7,000,000 (the “Principal”).
FPC OKSWF OR OR OSKGF FPRGF

33
Recommended Cash Offer by Orion Mine Finance to Acquire Dalradian Resources Inc.

2018-06-21 globenewswire
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) and Orion Mine Finance are pleased to announce that the Company and certain affiliates of Orion Mine Finance (collectively, “Orion”) have entered into a definitive arrangement agreement (the “Arrangement Agreement”), whereby Orion will acquire all of the issued and outstanding common shares of the Company (“Dalradian Shares”) by way of a statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).
DRLDF BLK DNA.WT.A FPC OKSWF DRRLF OR OSKGF FPRGF BGMZF DALR DNA

 
Osisko Acquires Silver Stream From Falco in Respect to the Horne 5 Project in Rouyn-Noranda, Quebec

2018-06-18 globenewswire
MONTRÉAL, June 18, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (TSX:OR) (NYSE:OR) is pleased to announce that it has entered into a binding term sheet to provide Falco Resources Ltd. (“Falco”) (TSXV:FPC) with a senior secured silver stream credit facility (“Silver Stream”) with reference to up to 100% of the future silver produced from the Horne 5 property (“Horne 5” or the “Project”) located in Rouyn-Noranda, Québec from Falco.
FPC OKSWF OR OR OSKGF BGMZF FPRGF

 
Falco Announces $180 Million Silver Stream Transaction and Concurrent $7 Million Debenture With Osisko Gold Royalties

2018-06-18 globenewswire
MONTREAL, June 18, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSXV:FPC) (“Falco” or the “Company”) is pleased to announce a financing transaction with Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”), pursuant to which Osisko has agreed to commit $180 million through a silver stream (the “Silver Stream Transaction”) toward the funding of the development of Falco’s Horne 5 Project (the “Project”).
FPC OKSWF OR OR OSKGF FPRGF

 
Falco and Osisko Agree to Extend Loan Maturity

2018-06-01 globenewswire
MONTREAL, June 01, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSX-V:FPC) (“Falco” or the “Company”) is pleased to announce that in connection with the C$10 million loan (“Loan”) provided by Osisko Gold Royalties Ltd (TSX:OR) (“Osisko”) on May 30, 2016, as amended, that both Falco and Osisko have agreed to extend the maturity to December 31st, 2018.
FPC OKSWF OR OR OSKGF FPRGF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 30606C959